Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting
Rhea-AI Summary
Seer (Nasdaq: SEER) reported that, based on preliminary results from its 2026 Annual Meeting of Stockholders, stockholders voted to re-elect all seven director nominees to the Board. The company said it remains focused on executing its strategy, including expanding platform utilization and commercialization with cost discipline. Final voting results will be certified by an independent inspector and filed on Form 8-K with the SEC.
Positive
- None.
Negative
- None.
News Market Reaction – SEER
In the Jul 29 session, SEER declined 2.80%, reflecting a moderate negative market reaction. Argus tracked a peak move of +15.0% during that session. Argus tracked a trough of -2.2% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.3x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 23 | Activist proxy campaign | Negative | -3.9% | Activist group urged votes for alternative nominees amid contested board election |
| Jul 20 | Director vote solicitation | Negative | -6.0% | Company urged support for incumbent director nominees during proxy contest |
| Jul 20 | Acquisition proposal rejection | Positive | -6.0% | Special committee rejected non-binding $2.45-per-share acquisition proposal with CVRs from CEO |
| Jul 17 | Activist campaign update | Negative | +0.5% | Activist group announced ISS support for its alternative director slate |
| Jul 14 | Shareholder letter | Neutral | +0.0% | Board issued shareholder letter during contested director election campaign |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent governance and strategic events showed mostly negative or flat 24-hour reactions, including -5.99% responses to a director-vote solicitation and an acquisition-proposal rejection.
Key Terms
form 8-k regulatory
biobank medical
cohort medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer”) today announced that, based on the preliminary voting results from Seer’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), Seer stockholders have voted to re-elect all seven of Seer’s director nominees – Omid Farokhzad, M.D.; Meeta Gulyani; Robert Langer, Sc.D.; Terrance McGuire; Dipchand (Deep) Nishar; Isaac Ro; and Nicolas Roelofs, Ph.D. – to Seer’s Board of Directors (the “Board”).
Seer issued the following statement:
We thank our stockholders for their support and engagement over the last several months. This outcome reflects confidence in Seer’s highly qualified, purpose-built Board and our directors’ commitment to advancing the best interests of all stockholders. We remain focused on disciplined execution of our strategy that includes expanding utilization of our growing installed base, securing additional population-scale cohort and biobank studies, advancing our innovation pipeline and scaling platform commercialization with continued cost discipline. The business is building momentum, and we remain confident in Seer’s ability to drive value creation over the long-term.
The voting results announced today are considered preliminary until final results are tabulated and certified by the independent inspector of elections. Seer expects to report the final certified voting results for all proposals on a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
For more information, please email us at pr@seer.bio.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this communication. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s strategy, execution and business momentum. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
pr@seer.bio
Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449
Investor Contact:
Marissa Bych
investor@seer.bio
